Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Meyer

Physician Assistant, Medical Lakewood, CO Physician Assistant

NPI 1588035117 CMS profile 11209118

13952 Denver West Pkwy Ste 100, Lakewood, CO 80401

Open in the dashboard

General payments

$9,871

463 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Meyer of Lakewood, CO is reported in the CMS Open Payments database as having received $9,871 across 463 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,101 91
2024 General $2,249 101
2023 General $2,025 93
2022 General $1,938 83
2021 General $1,557 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Meyer
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jennifer Meyer were reported at $2,101. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jennifer Meyer Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,557 $156 $41–$563 $132
2022 $1,938 $185 $55–$649 $149
2023 $2,025 $199 $58–$717 $160
2024 $2,249 $206 $62–$740 $164
2025 $2,101 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,811 150 payments
  2. Gilead Sciences, Inc. $1,265 53 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,028 38 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $841 40 payments
  5. Janssen Biotech, Inc. $697 29 payments
  6. Celgene Corporation $635 35 payments
  7. Lilly USA, LLC $417 11 payments
  8. Pfizer Inc. $401 24 payments
  9. Genzyme Corporation $289 14 payments
  10. Regeneron Healthcare Solutions, Inc. $259 13 payments
  11. Other $1,226 56 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,824 461 payments
  2. Education $47 2 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $807 38 payments
  2. RINVOQ $772 45 payments
  3. ENTYVIO $767 25 payments
  4. ZEPOSIA $741 36 payments
  5. SKYRIZI $660 31 payments
  6. HUMIRA $632 40 payments
  7. MAVYRET $432 26 payments
  8. STELARA $413 21 payments
  9. CREON $388 22 payments
  10. XELJANZ $367 22 payments
  11. Other $3,956 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,218

Median for Physician Assistant: 241

Drug cost

$918,615

Median for Physician Assistant: $4,110

Branded share of claims

30.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 48 $266,266
Ocaliva Obeticholic Acid Brand 17 $231,085
Zenpep Lipase/Protease/Amylase Brand 36 $165,925
Xeljanz Tofacitinib Citrate Brand 11 $73,479
Linzess Linaclotide Brand 62 $56,547
Xifaxan Rifaximin Brand 15 $37,350
Vemlidy Tenofovir Alafenamide Brand 11 $18,458
Motegrity Prucalopride Succinate Brand 12 $15,002
Dexlansoprazole Dr Dexlansoprazole Brand 32 $12,130
Mesalamine Generic 25 $6,434

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$29,627

Medicare's payments for the services billed

Medicare patients

233

Average age 74

Services billed

397

159 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 53%
Depression 29%
Osteoporosis 26%
Chronic kidney disease 25%
Ischemic heart disease 20%
Diabetes 17%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $335
$335 15 —
SKYRIZI
  • AbbVie, Inc. $231
$231 — —
DUPIXENT
  • GENZYME CORPORATION $110
  • Regeneron Healthcare Solutions, Inc. $78
$187 — —
RINVOQ
  • AbbVie, Inc. $155
$155 — —
OMVOH
  • Lilly USA, LLC $149
$149 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

463 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record